Small Gold Nanoparticles Alleviate Huntington's Disease via Modulating p38α Mitogen-Activated Protein Kinase and...

Area of Science:

• Nanomedicine
• Neurodegenerative disease research
• Gold nanoparticle applications

Background:

• Huntington's disease (HD) is a severe neurodegenerative disorder with limited effective treatments.
• Drug delivery to the brain for HD remains a significant challenge.
• Current therapies primarily offer symptomatic relief.

Purpose of the Study:

• To develop and evaluate a novel gold nanoparticle (NP) for brain delivery and treatment of Huntington's disease.
• To assess the NP's biodistribution, neuronal uptake, and therapeutic efficacy in an HD mouse model.
• To elucidate the molecular mechanisms underlying the NP's therapeutic effects.

Main Methods:

• Intravenous injection of polyethylene glycol-coated gold nanoparticles (∼11 nm) in R6/2 mice (HD model) and healthy littermates.
• Assessment of NP brain penetration, biodistribution (brain, liver, kidney), and cellular uptake (neurons, microglia).
• Evaluation of motor function, survival rates, and molecular pathways (oxidative phosphorylation, MAPK signaling, pyroptosis).

Main Results:

• The gold NP successfully crossed brain barriers and accumulated in the brains of R6/2 mice without significant off-target organ sequestration.
• The NP improved motor deficits and prolonged survival in HD mice, comparable to standard symptomatic therapy.
• Treatment activated oxidative phosphorylation, inhibited key signaling pathways (p38α MAPK, PDK1), and suppressed pyroptosis, demonstrating a drug-free therapeutic mechanism.

Conclusions:

• Small gold nanoparticles represent a viable platform for drug-free treatment of Huntington's disease.
• This nanomedicine demonstrates effective brain delivery, neuronal targeting, and significant therapeutic benefits in a preclinical HD model.
• The findings provide molecular insights into the potential of gold nanomedicines for neurodegenerative diseases.